Advisory Committee Nominations; Modification To Process for Collecting and Posting Curricula Vitae, 9382-9383 [2017-02411]
Download as PDF
9382
Federal Register / Vol. 82, No. 23 / Monday, February 6, 2017 / Notices
Minnesota, and thereby indirectly
acquire Signature Bank, Minnetonka,
Minnesota.
B. Federal Reserve Bank of San
Francisco (Gerald C. Tsai, Director,
Applications and Enforcement) 101
Market Street, San Francisco, California
94105–1579:
1. Carpenter Bank Partners, Inc.,
CCFW, Inc., Carpenter Fund Manager
GP, LLC, Carpenter Fund Management
Company, LLC, Carpenter Community
BancFund, L.P., Carpenter Community
BancFund-A, L.P., and Carpenter
Community BancFund, L.P., all Irvine,
California; to acquire Pacific Premier
Bancorp and thereby indirectly acquire
Pacific Premier Bank, Irvine, California.
Board of Governors of the Federal Reserve
System, January 31, 2017.
Yao-Chin Chao,
Assistant Secretary of the Board.
[FR Doc. 2017–02368 Filed 2–3–17; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0001]
Advisory Committee Nominations;
Modification To Process for Collecting
and Posting Curricula Vitae
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA, Agency, or we) is
modifying the process by which we
collect and post curricula vitae (CVs) of
advisory committee members so that the
CVs will be posted to our Web site
without removing or redacting any
information. Posting CVs without
removing or redacting any information
will increase the transparency of FDA’s
selection of officials who serve on
advisory committees, and will ensure
greater public access to the
qualifications of advisory committee
members on an ongoing basis. Because
advisory committee members are best
situated to determine whether there is
confidential information in their CVs,
this modified collection and posting
process will conserve FDA resources
because FDA personnel will no longer
be responsible for reviewing and
redacting the CVs.
DATES: All nominees for positions on an
FDA advisory committee will be
required to submit a consent form on or
after the date of the Office of
Management and Budget (OMB)
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
16:03 Feb 03, 2017
Jkt 241001
approval for this information collection,
authorizing FDA to publicly post an unredacted copy of their CV on FDA’s Web
site. Elsewhere in this issue of the
Federal Register, FDA is publishing the
notice for the proposed information
collection. Additionally, effective March
8, 2017, all existing advisory committee
members who submit an updated
version of their CV to FDA will be
required to submit a consent form along
with their CV.
FOR FURTHER INFORMATION CONTACT:
Questions should be sent electronically
to ACOMSSubmissions@fda.hhs.gov, or
by mail to Advisory Committee
Oversight and Management Staff, 10903
New Hampshire Ave., Bldg. 32, Rm.
5129, Silver Spring, MD 20993–0002.
SUPPLEMENTARY INFORMATION:
I. Background
FDA generally has posted the CVs of
FDA advisory committee members
publicly on https://www.fda.gov/
AdvisoryCommittees/ after reviewing
the CVs and redacting information that
appeared to be confidential. Currently,
FDA requires the submission of a CV for
each nominee as part of the nomination
process for advisory committee
members. FDA also requests that
existing advisory committee members
submit updated versions of their CVs,
typically on a yearly basis.
In furtherance of FDA’s goal of
ensuring transparency regarding the
qualifications of individuals selected to
serve on FDA advisory committees, and
in recognition that individual advisory
committee members are best situated to
evaluate the confidentiality of
information contained in their CVs,
including any considerations raised by
their relationships and agreements with
third parties, FDA will be requiring that
all CVs submitted as part of the
nomination process for positions on
FDA advisory committees be
accompanied by a written consent form
stating that, if the nominee is accepted
as a member of an FDA advisory
committee, the individual consents to
the publication of the individual’s CV to
FDA’s Web site, without FDA removing
or redacting any information. The
consent form requires that the nominee
affirm that the CV does not include any
confidential information, including
information pertaining to third parties
that the nominee is not permitted to
disclose. A nominee will be required to
submit a signed consent form in order
for the nomination to be considered
complete. The consent form will need to
be submitted along with the four other
types of documents currently requested
as part of the nomination process: (1) A
PO 00000
Frm 00013
Fmt 4703
Sfmt 4703
CV for each nominee; (2) a written
confirmation that the nominee is aware
of the nomination (unless selfnominated); (3) a letter(s) of
recommendation; and (4) for Consumer
Representative applications, a cover
letter that lists consumer or community
organizations for which the candidate
can demonstrate active participation. In
addition to the consent form submitted
as part of the application process, FDA
will also be requiring that a nearly
identical consent form be submitted by
all existing advisory committee
members each time they submit an
updated version of their CV to FDA. The
language of the consent for existing
advisory committee members will differ
only in that it will not include the
language ‘‘if [the nominee is] selected to
serve on an [FDA] advisory committee’’.
Every day, FDA makes important
health and safety decisions about foods,
drugs, medical devices, cosmetics, and
other widely used consumer products.
Transparency in FDA’s activities and
decision making allows the public to
better understand the Agency’s
decisions, increasing credibility and
promoting accountability. Transparency
helps the Agency to more effectively
protect and promote the public health.
Ensuring greater public awareness of the
qualifications of individuals responsible
for assisting the Agency in making
important policy decisions is an
important factor in ensuring such
transparency. Posting the CVs of
advisory committee members helps
increase public awareness.
Additionally, requiring advisory
committee nominees and advisory
committee members to attest that their
CVs do not include any confidential
information, including information
pertaining to third parties that they are
not permitted to disclose, will help
conserve limited FDA resources by
ensuring that the individual most
familiar with the information contained
in the CV, as well as any contractual or
confidentiality agreements that might
affect their ability to disclose that
information, assumes the responsibility
for determining whether the information
may be released publicly. Because
advisory committee nominees and
members are most familiar with the
information contained in their CVs,
FDA will not be advising potential or
current members about whether specific
information in their CVs is confidential
or otherwise should be removed.
II. Advisory Committee Member CVs
and Confidential Information
The consent form will be required to
be submitted each time an advisory
committee nominee’s or existing
E:\FR\FM\06FEN1.SGM
06FEN1
Federal Register / Vol. 82, No. 23 / Monday, February 6, 2017 / Notices
advisory committee member’s CV is
submitted to FDA. All information
contained in the CV submission for
individuals who are selected for or
currently serving on an FDA advisory
committee will be available for public
posting. Specifically, for nominees for
positions on an FDA advisory
committee, the required consent will
state as follows:
ACTION:
For existing advisory committee
members who submit updated CVs, the
required consent will state as follows:
I consent to publication of my curriculum
vitae (CV), and any subsequent updates to my
CV that I provide FDA, on FDA’s Web site,
without removing or redacting any
information. My CV does not include any
confidential information, including
information pertaining to third parties that I
am not permitted to disclose.
III. Date of Implementation
All nominations for new advisory
committee members will be required to
be submitted through FDA’s Web site at
https://www.accessdata.fda.gov/scripts/
FACTRSPortal/FACTRS/index.cfm, or
any successor system, and the
submission will be required to be
accompanied by the required consent
form, on or after the date of OMB
approval for this information collection.
All updated CVs for existing advisory
committee members will be required to
be submitted to FDA along with the
required consent form after March 8,
2017.
Dated: February 1, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017–02411 Filed 2–3–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
sradovich on DSK3GMQ082PROD with NOTICES
[Docket No. FDA–2017–N–0366]
Agency Information Collection
Activities: Proposed Collection;
Comment Request; Collection of
Nominations for Candidates To Serve
on the Food and Drug Administration’s
Advisory Committees
Food and Drug Administration,
HHS.
VerDate Sep<11>2014
16:03 Feb 03, 2017
Jkt 241001
The Food and Drug
Administration (FDA or Agency) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on the Agency’s
process for collecting nominations of
candidates to serve on FDA’s advisory
committees.
DATES: Submit either electronic or
written comments on the collection of
information by April 7, 2017.
ADDRESSES: You may submit comments
as follows:
SUMMARY:
If I am selected to serve on an advisory
committee, I consent to publication of my
curriculum vitae (CV), and any subsequent
updates to my CV that I provide FDA, on
FDA’s Web site, without removing or
redacting any information. My CV does not
include any confidential information,
including information pertaining to third
parties that I am not permitted to disclose.
AGENCY:
Notice.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
PO 00000
Frm 00014
Fmt 4703
Sfmt 4703
9383
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2017–N–0366 for ‘‘Agency Information
Collection Activities: Proposed
Collection; Comment Request;
Collection of Nominations for
Candidates to Serve on FDA’s Advisory
Committees.’’ Received comments will
be placed in the docket and, except for
those submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
E:\FR\FM\06FEN1.SGM
06FEN1
Agencies
[Federal Register Volume 82, Number 23 (Monday, February 6, 2017)]
[Notices]
[Pages 9382-9383]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-02411]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-N-0001]
Advisory Committee Nominations; Modification To Process for
Collecting and Posting Curricula Vitae
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is
modifying the process by which we collect and post curricula vitae
(CVs) of advisory committee members so that the CVs will be posted to
our Web site without removing or redacting any information. Posting CVs
without removing or redacting any information will increase the
transparency of FDA's selection of officials who serve on advisory
committees, and will ensure greater public access to the qualifications
of advisory committee members on an ongoing basis. Because advisory
committee members are best situated to determine whether there is
confidential information in their CVs, this modified collection and
posting process will conserve FDA resources because FDA personnel will
no longer be responsible for reviewing and redacting the CVs.
DATES: All nominees for positions on an FDA advisory committee will be
required to submit a consent form on or after the date of the Office of
Management and Budget (OMB) approval for this information collection,
authorizing FDA to publicly post an un-redacted copy of their CV on
FDA's Web site. Elsewhere in this issue of the Federal Register, FDA is
publishing the notice for the proposed information collection.
Additionally, effective March 8, 2017, all existing advisory committee
members who submit an updated version of their CV to FDA will be
required to submit a consent form along with their CV.
FOR FURTHER INFORMATION CONTACT: Questions should be sent
electronically to ACOMSSubmissions@fda.hhs.gov, or by mail to Advisory
Committee Oversight and Management Staff, 10903 New Hampshire Ave.,
Bldg. 32, Rm. 5129, Silver Spring, MD 20993-0002.
SUPPLEMENTARY INFORMATION:
I. Background
FDA generally has posted the CVs of FDA advisory committee members
publicly on https://www.fda.gov/AdvisoryCommittees/ after reviewing the
CVs and redacting information that appeared to be confidential.
Currently, FDA requires the submission of a CV for each nominee as part
of the nomination process for advisory committee members. FDA also
requests that existing advisory committee members submit updated
versions of their CVs, typically on a yearly basis.
In furtherance of FDA's goal of ensuring transparency regarding the
qualifications of individuals selected to serve on FDA advisory
committees, and in recognition that individual advisory committee
members are best situated to evaluate the confidentiality of
information contained in their CVs, including any considerations raised
by their relationships and agreements with third parties, FDA will be
requiring that all CVs submitted as part of the nomination process for
positions on FDA advisory committees be accompanied by a written
consent form stating that, if the nominee is accepted as a member of an
FDA advisory committee, the individual consents to the publication of
the individual's CV to FDA's Web site, without FDA removing or
redacting any information. The consent form requires that the nominee
affirm that the CV does not include any confidential information,
including information pertaining to third parties that the nominee is
not permitted to disclose. A nominee will be required to submit a
signed consent form in order for the nomination to be considered
complete. The consent form will need to be submitted along with the
four other types of documents currently requested as part of the
nomination process: (1) A CV for each nominee; (2) a written
confirmation that the nominee is aware of the nomination (unless self-
nominated); (3) a letter(s) of recommendation; and (4) for Consumer
Representative applications, a cover letter that lists consumer or
community organizations for which the candidate can demonstrate active
participation. In addition to the consent form submitted as part of the
application process, FDA will also be requiring that a nearly identical
consent form be submitted by all existing advisory committee members
each time they submit an updated version of their CV to FDA. The
language of the consent for existing advisory committee members will
differ only in that it will not include the language ``if [the nominee
is] selected to serve on an [FDA] advisory committee''.
Every day, FDA makes important health and safety decisions about
foods, drugs, medical devices, cosmetics, and other widely used
consumer products. Transparency in FDA's activities and decision making
allows the public to better understand the Agency's decisions,
increasing credibility and promoting accountability. Transparency helps
the Agency to more effectively protect and promote the public health.
Ensuring greater public awareness of the qualifications of individuals
responsible for assisting the Agency in making important policy
decisions is an important factor in ensuring such transparency. Posting
the CVs of advisory committee members helps increase public awareness.
Additionally, requiring advisory committee nominees and advisory
committee members to attest that their CVs do not include any
confidential information, including information pertaining to third
parties that they are not permitted to disclose, will help conserve
limited FDA resources by ensuring that the individual most familiar
with the information contained in the CV, as well as any contractual or
confidentiality agreements that might affect their ability to disclose
that information, assumes the responsibility for determining whether
the information may be released publicly. Because advisory committee
nominees and members are most familiar with the information contained
in their CVs, FDA will not be advising potential or current members
about whether specific information in their CVs is confidential or
otherwise should be removed.
II. Advisory Committee Member CVs and Confidential Information
The consent form will be required to be submitted each time an
advisory committee nominee's or existing
[[Page 9383]]
advisory committee member's CV is submitted to FDA. All information
contained in the CV submission for individuals who are selected for or
currently serving on an FDA advisory committee will be available for
public posting. Specifically, for nominees for positions on an FDA
advisory committee, the required consent will state as follows:
If I am selected to serve on an advisory committee, I consent to
publication of my curriculum vitae (CV), and any subsequent updates
to my CV that I provide FDA, on FDA's Web site, without removing or
redacting any information. My CV does not include any confidential
information, including information pertaining to third parties that
I am not permitted to disclose.
For existing advisory committee members who submit updated CVs, the
required consent will state as follows:
I consent to publication of my curriculum vitae (CV), and any
subsequent updates to my CV that I provide FDA, on FDA's Web site,
without removing or redacting any information. My CV does not
include any confidential information, including information
pertaining to third parties that I am not permitted to disclose.
III. Date of Implementation
All nominations for new advisory committee members will be required
to be submitted through FDA's Web site at https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm, or any
successor system, and the submission will be required to be accompanied
by the required consent form, on or after the date of OMB approval for
this information collection. All updated CVs for existing advisory
committee members will be required to be submitted to FDA along with
the required consent form after March 8, 2017.
Dated: February 1, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-02411 Filed 2-3-17; 8:45 am]
BILLING CODE 4164-01-P